🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 52 of 857 · Phase 3 first, then by program name

  1. Datopotamab deruxtecan, Rilvegostomig, MYCOPHENOLATE MOFETIL, INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    AstraZeneca AB

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  2. Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, Matching placebo tablets without active substance, Idarubicin Ebewe 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Quizartinib, Citarabina Hikma 100mg/5mL Soluzione Iniettabile, Quizartinib

    Daiichi Sankyo

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  3. Daunorubicin/Idarubicin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML, Adult

    phase 3 small molecule active

    1 trial

  4. Dazodalibep

    Amgen

    Sjögren’s Syndrome

    phase 3 small molecule active

    1 trial

  5. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The nominal volume in each vial is 5.0 mL. The placebo is aseptically filled into 6R glass vials, stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-toSevere Symptom State

    phase 3 small molecule active

    1 trial

  6. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The placebo is aseptically filled into 6R glass vials( the nominal volume in each vial is 5.0 mL) and 20R glass vials (the nominal volume in each vial is 15.0 mL) , stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity

    phase 3 small molecule active

    1 trial

  7. De-escalation to ticagrelor 60 mg at day 30

    COLLEGIUM PHARMACEUTICAL, INC

    Non ST Segment Elevation Acute Coronary Syndrome

    phase 3 small molecule active

    1 trial

  8. Debamestrocel - MSC-NTF (NurOwn)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 mab active

    1 trial

  9. Decartes-08

    Cartesian Therapeutics

    Myasthaenia Gravis

    phase 3 mab active

    1 trial

  10. Decitabine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial

  11. Decitabine

    The First People's Hospital of Lianyungang

    Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  12. Decitabine

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  13. Decitabine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Myelodysplastic Syndrome

    phase 3 small molecule completed

    1 trial

  14. Decitabine plus HAAG regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  15. Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF

    Hospital Authority, Hong Kong

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  16. Deferasirox

    Novartis Pharmaceuticals

    Transfusion-dependent Iron Overload

    phase 3 small molecule completed

    1 trial

  17. Deferiprone oral solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule completed

    1 trial

  18. Defibrotide

    Jazz Pharmaceuticals Ireland Limited

    Veno-occlusive Disease

    phase 3 small molecule completed

    2 trials

  19. Defibrotide

    Jazz Pharmaceuticals Ireland Limited

    Hepatic Veno-Occlusive Disease

    phase 3 small molecule completed

    2 trials

  20. Defibrotide

    Jazz Pharmaceuticals Ireland Limited

    Severe Hepatic Veno-Occlusive Disease

    phase 3 small molecule completed

    1 trial

  21. Deflazacort

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    3 trials

  22. Deflazacort

    PTC THERAPEUTICS, INC.

    Limb-Girdle Muscular Dystrophy

    phase 3 small molecule terminated

    1 trial

  23. Delamanid + OBR

    Otsuka Beijing Research Institute

    Multidrug-resistant Tuberculosis

    phase 3 small molecule completed

    1 trial

  24. Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources